- Home
- FRD vs XGN Comparison
FRD vs XGN Comparison
Compare FRD & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRD | XGN |
|---|---|---|
| Founded | 1965 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 110.7M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FRD | XGN |
|---|---|---|
| Price | $35.37 | $6.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.86 |
| AVG Volume (30 Days) | 73.2K | ★ 220.3K |
| Earning Date | 06-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $121,157,278.00 | N/A |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | N/A | $13.00 |
| P/E Ratio | $23.33 | ★ N/A |
| Revenue Growth | ★ 55.82 | N/A |
| 52 Week Low | $15.10 | $2.59 |
| 52 Week High | $39.07 | $12.23 |
Technical Indicators
Market Signals| Indicator | FRD | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.75 | N/A |
| Support Level | $30.68 | N/A |
| Resistance Level | $37.08 | N/A |
| Average True Range (ATR) | 2.31 | 0.00 |
| MACD | -0.32 | 0.00 |
| Stochastic Oscillator | 44.34 | 0.00 |
Price Performance
Historical ComparisonAbout FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.